$PYXS

Pyxis Oncology (PYXS) reported positive Phase 1 data for MICVO in 2L+ head and neck cancer, showing 36% cORR and 94% DCR. Median PFS was 6.2 months, with 79% 12-month survival. No new safety signals were observed. Pyxis plans a Phase 3 trial in mid-2027, pending FDA alignment. PYXS stock is down 16.95% in pre-market trading.

Modular Medical (MODD) rose 13.48% in overnight trading after a 23.37% drop earlier, planning a 2026 launch for its Pivot tubeless patch pump. Jin Medical (ZJYL) gained 20.79% with no specific news. InnovAge (INNV) increased 9.51% after reporting a 15.9% revenue rise. Pyxis Oncology (PYXS) climbed 5% ahead of a key clinical update. Pulse Biosciences (PLSE) fell 2.48% despite clinical trial progress. Dermata (DRMA) rose 7.20% after launching its Tome skincare brand. Dogwood Therapeutics (DWTX) ga

Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board John Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board Leadership transition reflects continued focus on advancing MICVO through key clin

Pro-Dex (PDEX) reported strong fiscal 2026 results with 17% Q4 sales growth and 16% annual sales increase. Modular Medical (MODD) gained FDA clearance for Pivot pump software. ENvue Medical (FEED) selected for Vizient Innovative Technology Exchange. Attovia (ATTO) and Pyxis Oncology (PYXS) provided clinical updates and financials. All stocks rose Friday.

Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of pat

Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 pyxs-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND AMONG PYXIS ONCOLOGY, INC., AND THE PURCHASERS AS SET FORTH HEREIN June 30, 2026 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Securities 6 2.1 Purchase and Sale 6 2.2 Closing

Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001782223 0001782223 2026-06-15 2026-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15,

Pyxis Oncology, Inc. (NASDAQ: PYXS) filed an amended Form 8-K/A report with the SEC, announcing the departure of its CEO, Lara Sullivan, M.D., effective February 2, 2026. The filing also details a Separation and General Release Agreement between the company and Dr. Sullivan. Investors are advised to monitor future announcements regarding new leadership and potential strategic changes.

Pyxis Oncology reported its fourth quarter and full-year 2025 financial results, alongside a business update highlighting the completion of target enrollment for its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in R/M HNSCC. The company expects updated data from this study mid-2026, which will include results from modified weight-based dosing. Pyxis Oncology also announced leadership appointments and has a cash runway extending into the fourth quarter of 2026.

Pyxis Oncology completed target enrollment in its Phase 1 monotherapy dose expansion study for MICVO in head and neck cancer and anticipates updated data mid-2026 for monotherapy and 2H26 for combination therapy. The company reported $68.3 million in cash, which is expected to fund operations into Q4 2026. Pyxis also announced the appointment of Thomas Civik as Interim CEO and completed an $11 million upfront royalty sale for Enzeshu rights.